Adc Therapeutics Sa (($~~ADCT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ADC Therapeutics S.A. is conducting a Phase 1b clinical study titled ‘A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)’. The study aims to determine the optimal dosing regimen of loncastuximab tesirine for patients with these types of lymphoma who also have moderate to severe liver impairment, which is crucial for tailoring treatment to this specific patient group.
The intervention being tested is loncastuximab tesirine, an intravenous drug designed to target and treat diffuse large B-cell lymphoma and high-grade B-cell lymphoma. The drug is administered in varying doses depending on the level of hepatic impairment, with adjustments made based on patient tolerance.
This interventional study employs a non-randomized, parallel assignment model with no masking, focusing on basic science to understand the drug’s pharmacokinetics and safety profile. The study’s design allows for dose adjustments based on patient reactions, ensuring safety and efficacy.
The study began on August 28, 2023, and is currently recruiting participants. The last update was submitted on July 14, 2025, indicating ongoing progress. These dates are significant as they provide a timeline for investors to gauge the study’s development and potential market entry.
The outcome of this study could significantly impact ADC Therapeutics’ stock performance, as positive results may enhance investor confidence and market position. The study’s focus on a niche patient group with hepatic impairment could differentiate ADC Therapeutics from competitors, potentially offering a unique market advantage.
The LOTIS-10 study is ongoing, with further details available on the ClinicalTrials portal.